SCHEMBL6205699

SCHEMBL6205699

CCc1ccc(Nc2c(-c3nnc(NCCO)o3)ccc(F)c2F)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 5/20 0.37
MAP2K2 P36507 3/20 0.37
KDR P35968 3/20 0.35
CYP3A4 P08684 1/20 0.35
PDCD1 Q15116 5/20 0.35
CD274 Q9NZQ7 5/20 0.35
CHRNA7 P36544 2/20 0.34
KCNH2 Q12809 2/20 0.34
ADCY1 Q08828 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
FLT1 P17948 2/20 0.33
TUBB4A P04350 2/20 0.32
TUBB P07437 2/20 0.32
TUBA3C P0DPH7 2/20 0.32
TUBA1B P68363 2/20 0.32
TUBA4A P68366 2/20 0.32
TUBB4B P68371 2/20 0.32
TUBB3 Q13509 2/20 0.32
TUBB2A Q13885 2/20 0.32
TUBB8 Q3ZCM7 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6399433 0.91 MAP2K1 (0.37) MAP2K1MAP2K2KDRCYP3A4PDCD1
SCHEMBL6398977 0.90 KDR (0.34) MAP2K1MAP2K2KDRCHRNA7KCNH2
SCHEMBL6207867 0.89 CHRNA7 (0.33) MAP2K1MAP2K2KDRCYP3A4CHRNA7
SCHEMBL6207302 0.88 PDCD1 (0.39) MAP2K1MAP2K2KDRCYP3A4PDCD1
SCHEMBL6207184 0.87 FLT1 (0.39) KDRFLT1
SCHEMBL6191149 0.87 MAP2K1 (0.35) MAP2K1MAP2K2KDRADCY1RXFP1
SCHEMBL6186912 0.87 MAP2K1 (0.35) MAP2K1MAP2K2KDRADCY1RXFP1
SCHEMBL6230975 0.87 CHRNA7 (0.34) KDRCYP3A4CHRNA7KCNH2FLT1
SCHEMBL6187962 0.86 CHRNA7 (0.34) MAP2K1MAP2K2CYP3A4CHRNA7KCNH2
SCHEMBL6208327 0.86 MAP2K1 (0.52) MAP2K1MAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
EP-1578736-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES Warner-Lambert Company LLC (US) 2005-09-28 EP disclosed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed
WO-2004056789-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES WARNER-LAMBERT COMPANY LLC (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 MAP2K1 46/4885MAP2K2 40/4885KDR 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.